New treatment for myocardial diseases
Kenji Onoue1, Yoshihiko Saito1
1Cardiovascular Medicine, Nara Medical University, Nara, Japan.
Journal of Cardiology
|November 30, 2020
Summary
Novel treatments targeting the molecular basis of myocardial diseases are emerging, offering more specific and effective therapies beyond traditional non-specific drugs. These advancements promise improved outcomes for conditions like cardiomyopathy and myocarditis.
Area of Science:
- Cardiology and Molecular Medicine
- Development of novel therapeutics for heart conditions
Background:
- Traditional treatments for myocardial diseases, such as renin-angiotensin system inhibitors and beta-blockers, have improved prognosis but are non-specific.
- Radical, cause-specific treatments for myocardial diseases have been limited until recent years.
- Recent advancements focus on molecular mechanisms underlying disease onset.
Purpose of the Study:
- To outline the mechanism of action of novel therapeutic agents for myocardial diseases.
- To present clinical data on emerging specific treatments.
- To cover conditions including dilated cardiomyopathy, hypertrophic cardiomyopathy, Fabry disease, cardiac amyloidosis, and myocarditis.
Main Methods:
- Review of molecular mechanisms driving myocardial diseases.
- Analysis of emerging therapeutic agents targeting these mechanisms.
- Compilation of clinical data and approved treatments.
Main Results:
- Development of specific, upstream treatments based on molecular mechanisms.
- Demonstrated efficacy of some novel agents in clinical practice.
- Approval of certain new therapies.
Conclusions:
- Novel molecularly targeted therapies are transforming myocardial disease treatment.
- Continued elucidation of molecular mechanisms will drive future therapeutic innovations.
- Emerging treatments offer more specific and potentially curative options for heart conditions.
Related Concept Videos
01:14Myocarditis III: Medical Management
86
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
86
01:29Cardiomyopathy V: Interprofessional Care
143
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
143
01:30Cardiomyopathy II: Dilated Cardiomyopathy
219
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
219
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
191
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
191
01:26Heart Failure Drugs: Inotropic Agents
959
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
959
01:27Coronary Artery Disease V: Interprofessional Care
135
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
135